New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...
In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...
Global warming has accelerated in a "statistically significant" way since 2015, according to a study published by the Potsdam Institute for Climate Impact Research (PIK)."Over the past 10 years, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results